Scientific deep-dive

Ozempic Muscle Loss & Lean Mass Protection: Honest Evidence Review

Muscle loss on Ozempic is real but proportional to weight-loss rate, not unique to the drug. SURMOUNT-1 DXA: about 25% of weight lost was lean tissue, the same share as on placebo. Resistance training 2-3x/week + 1.2-1.6 g/kg protein is the protective intervention.

By Eli Marsden · Founding Editor
Editorially reviewed & fact-checked against primary sources · How we verify contentLast reviewed
13 min read·13 citations

The honest answer

Muscle loss on Ozempic is real — but it is PROPORTIONAL to the rate of weight loss, not unique to the drug. SURMOUNT-1 DXA data shows about 25% of weight lost was lean tissue, the same share as in the placebo arm. The protective intervention is resistance training 2-3x/week plus 1.2-1.6 g/kg protein per day. DXA measurement at baseline and every 6 months is gold-standard tracking.

“Does Ozempic cause muscle loss?” is one of the most common patient questions about semaglutide therapy, and it has a more nuanced answer than the viral TikTok framing suggests. Yes, a portion of the weight lost on Ozempic is lean tissue rather than fat — this is well-documented in the SURMOUNT-1 DXA substudy on tirzepatide[1] and in cross-trial estimates for semaglutide. But the lean-tissue percentage of total weight loss was the same share as in the placebo arm, not a uniquely drug-induced phenomenon. The Ozempic prescribing information does not list muscle loss, sarcopenia, or myopathy as a labeled adverse reaction. What matters more than the drug choice is whether the patient is doing the two interventions with the strongest evidence for preserving muscle in a caloric deficit: resistance training 2-3 days per week and adequate protein.

What “muscle loss on Ozempic” actually means

When someone loses weight — whether on a GLP-1, in a diet study, after bariatric surgery, or in caloric restriction without any intervention — the weight that comes off is not pure body fat. It is a mix of fat mass and lean tissue, where “lean tissue” on a DXA scan includes skeletal muscle, organ tissue, bone-attached connective tissue, and intracellular water in lean compartments. The classic body composition ratio for moderate-rate weight loss in mixed-age adults is roughly 75% fat mass and 25% lean mass. Faster weight loss tilts the ratio toward more lean tissue lost; slower weight loss with high protein and resistance training tilts it toward more fat.

Ozempic (semaglutide 2.4 mg as Wegovy, 0.5-2.0 mg as Ozempic for T2D, off-label use for weight loss) produced a mean 14.9% body weight loss in the STEP-1 pivotal trial, versus 2.4% with placebo, over 68 weeks[2]. The composition of that weight loss is the relevant clinical question. Direct semaglutide DXA data is more limited than tirzepatide data, so the best reference point is the SURMOUNT-1 DXA substudy[1] on tirzepatide (pooled doses over 72 weeks): about 25% of total weight lost was lean tissue and about 75% was fat, and those proportions held across most subgroups, including age groups.

The framing matters. “Ozempic causes muscle wasting” is misleading. “Ozempic produces weight loss, and the composition of that weight loss follows the same physiology as any rapid weight loss — meaning a portion is lean tissue, and the percentage can be optimized with resistance training and protein” is the accurate version.

What SURMOUNT-1 DXA data showed (Look 2025)

Look and colleagues[1] published the SURMOUNT-1 DXA body composition substudy in Diabetes, Obesity and Metabolism in 2025. SURMOUNT-1 was the pivotal Phase 3 trial of tirzepatide (Zepbound, marketed by Eli Lilly) in adults with obesity over 72 weeks. The DXA substudy enrolled a sub-cohort of the main trial and reported:

  • Total body weight reduction: −21.3% at Week 72 (pooled tirzepatide doses).
  • Total fat mass reduction: −33.9%.
  • Total lean mass reduction: −10.9%.
  • Composition of weight lost: approximately 75% fat, 25% lean — the same split seen in the placebo arm.

The placebo arm in the DXA substudy showed a similar 75/25 fat- to-lean ratio of weight lost, supporting the conclusion that the body composition split is NOT a tirzepatide-specific pharmacological effect but a generic consequence of the rate and total amount of weight lost. Direct semaglutide DXA data from the STEP program is less granular, and across GLP-1 trials the lean share varies widely: Neeland and colleagues report lean mass making up anywhere from about 15% or less to 40% to 60% of total weight lost, depending on the study[8].

Is the lean-mass % abnormal? Cross-trial comparison

The clinically important question is whether losing about a quarter of the weight as lean tissue is abnormal. The matching placebo split suggests it is not. Cava and colleagues[9] reviewed the muscle-preservation literature in Advances in Nutrition and reported that diet-induced weight loss reduces muscle mass without adversely affecting muscle strength, and that weight loss improves overall physical function, most likely because of reduced fat mass.

Neeland and colleagues[8] reviewed the GLP-1 lean mass literature in Diabetes, Obesity and Metabolism in 2024 and concluded that skeletal muscle changes on GLP-1 therapy appear adaptive (reductions in muscle volume roughly match what is expected given age, disease status, and the weight lost, alongside improved insulin sensitivity and less fat inside muscle), but that older age and more severe disease may affect who is a good candidate because of sarcopenia risk. The two levers with the best evidence, covered below, are adequate protein and structured resistance training at least 2-3 times per week. Preserving muscle isn't only about strength: because lean mass is the main driver of resting energy expenditure, losing it lowers the metabolic rate — one reason GLP-1 weight loss can stall, as we cover in do GLP-1 drugs speed up or slow your metabolism?

The honest framing for patients: the lean-tissue share of weight lost on Ozempic is what physiology predicts for the rate of weight loss the drug produces. It is not a uniquely worrying drug effect. The question that matters is whether the patient is doing the interventions that bend the body composition split toward more fat and less lean tissue.

Magnitude comparison

Composition of weight lost on tirzepatide (SURMOUNT-1 DXA substudy, Look 2025). Roughly 75% of total weight lost was fat mass, 25% lean tissue, the same share as in the placebo arm. Resistance training plus adequate protein can shift this ratio toward more fat and less lean.[1]

  • Fat mass reduction (% of starting fat mass)33.9 % ↓
    the desired body composition change
  • Total body weight reduction (% of starting weight)21.3 % ↓
    pooled tirzepatide doses, 72 weeks
  • Lean mass reduction (% of starting lean mass)10.9 % ↓
    ~25% of total weight lost was lean tissue — proportional, not abnormal
Composition of weight lost on tirzepatide (SURMOUNT-1 DXA substudy, Look 2025). Roughly 75% of total weight lost was fat mass, 25% lean tissue, the same share as in the placebo arm. Resistance training plus adequate protein can shift this ratio toward more fat and less lean.

Resistance training is the primary protective lever

The single highest-evidence intervention for preserving lean mass during weight loss is resistance training, and the canonical RCT in the relevant population is Villareal 2017 NEJM [3]. Villareal and colleagues randomized 160 older adults (65+) with obesity to one of four arms for 6 months: (1) control; (2) aerobic exercise only; (3) resistance training only; (4) combined aerobic + resistance training. All intervention arms followed the same caloric deficit. The key body composition results:

  • Combined aerobic + resistance: the largest improvements in physical function (Physical Performance Test score), VO2 peak, AND the best preservation of lean mass relative to the aerobic-only group.
  • Resistance training only: preserved lean mass better than aerobic exercise alone, with strength gains and modest functional benefit.
  • Aerobic exercise only: produced the most lean mass LOSS of the intervention arms — cardio without resistance training is not protective.
  • Control (caloric deficit, no exercise): produced the largest lean mass loss overall.

The Villareal 2017 trial[3] was performed in older adults specifically because the consequences of lean mass loss are most clinically relevant in that population (sarcopenia, fragility fractures, loss of independence). The directional finding generalizes to younger adults on GLP-1 therapy: cardio alone is not protective, resistance training is. The compound lifts — squat, hinge (deadlift or Romanian deadlift), horizontal push (dumbbell press or push-up), horizontal pull (row or pull-up), and carry (farmer carry or sled push) — deliver the most muscle recruitment per training session and are the highest-leverage exercises for limited weekly volume.

Practical prescription from Villareal 2017 and the ACSM position stands referenced in our companion exercise pairing on a GLP-1 evidence review: 2-3 resistance training sessions per week, 45-60 minutes per session, 8-10 exercises targeting major muscle groups, 8-12 reps per set, 2-4 sets per exercise, with progressive overload week to week.

Protein 1.2-1.6 g/kg lean body mass — what the evidence shows

Two anchor papers establish the protein dose for lean mass preservation during weight loss. Pasiakos and colleagues [5] reviewed the optimized dietary strategies for protecting skeletal muscle during energy deficit in FASEB Journal in 2015. The pooled evidence from controlled feeding studies indicated that 1.5-2.0 g/kg/day of high-quality protein consumed across 3-4 evenly spaced meals (each containing ~0.25-0.40 g/kg) is the threshold dose for preserving skeletal muscle mass during a 30-40% energy deficit.

Phillips and colleagues[4] published the canonical protein-requirements-beyond-the-RDA review in Applied Physiology, Nutrition, and Metabolism in 2016, arguing that the 0.8 g/kg/day RDA is the minimum to prevent nitrogen balance loss in sedentary adults — not the optimal intake for adults pursuing weight loss, strength training, or aging-related muscle preservation. The Phillips 2016 framework recommends 1.2-1.6 g/kg/day for older adults, active adults, and adults in a caloric deficit, with the upper end (1.6-2.0 g/kg) for those with the most aggressive muscle-preservation goals.

The ISSN Position Stand on protein and exercise (Jäger 2017[6]) consolidates the position: 1.4-2.0 g/kg/day for active individuals, distributed as 0.25-0.40 g/kg per meal across 3-4 daily meals, with the higher end of the range recommended during caloric restriction to support lean mass retention.

For Ozempic patients specifically, the practical challenge is meeting the protein target on a suppressed appetite. Many patients drop their daily caloric intake by 30-50% on Ozempic without explicitly tracking protein, ending up at 50-70 g/day when their target should be 90-130 g/day for a 60-80 kg adult. Our GLP-1 protein & macro calculator gives a personalized target. For specific food choices that hit the threshold dose efficiently, see our what to eat the first month on Ozempic guide and the best protein powder for weight loss evidence review.

Creatine 3-5g/day — does it help?

The ISSN Position Stand on creatine (Kreider 2017 [7]) classifies creatine monohydrate as the most effective ergogenic nutritional supplement for increasing lean body mass in conjunction with resistance training, with decades of safety data in healthy adults. The standard dose is 3-5 g/day, with optional loading (20 g/day for 5-7 days) for faster intracellular saturation.

Direct creatine + Ozempic trial data does not yet exist, but the mechanistic case is straightforward: creatine amplifies the muscle-protein-synthesis response to resistance training, which is the primary lever for lean mass preservation. There is no documented pharmacokinetic interaction between creatine and semaglutide, and creatine is not listed in the Ozempic FDA label Section 7 (Drug Interactions) as a contraindicated or cautioned combination.

The clinically relevant consideration is hydration. Creatine increases intracellular water retention by ~0.5-1.5 kg in the first 1-4 weeks of use, and Ozempic GI side effects (nausea, vomiting, diarrhea) can cause dehydration. Adequate fluid intake is important when using both. During the Ozempic dose- titration window (when GI symptoms peak), patients should skip the loading phase and begin directly at 3-5 g/day maintenance. For the full creatine + GLP-1 evidence picture, see our GLP-1 + creatine for lean mass preservation evidence review.

Elderly + sarcopenia population — extra precautions

The clinical stakes of lean mass loss are highest in adults over 65, who have a higher baseline risk of sarcopenia (age-related muscle loss), fragility fractures, and loss of functional independence. The Villareal 2017 NEJM trial [3] was specifically designed to address this population and showed that combined aerobic + resistance training preserved lean mass AND improved physical function during weight loss in obese older adults — meaning the weight loss can be net beneficial in this population when paired with the right exercise stimulus, but harmful when pursued via diet alone.

Practical implications for older adults on Ozempic:

  • DXA monitoring is standard, not optional. Baseline DXA scan plus follow-up every 6 months to track lean mass and bone mineral density.
  • Structured resistance training is required. Working with a credentialed exercise physiologist or physical therapist for the first 4-12 weeks of training to establish safe form is reasonable.
  • Protein target is higher. The PROT-AGE position paper[13] recommends at least 1.0-1.2 g/kg/day for adults over 65, at least 1.2 g/kg/day for those who exercise or are otherwise active, and 1.2-1.5 g/kg/day for most older adults with acute or chronic disease; people with severe kidney disease who are not on dialysis are an exception and may need to limit protein.
  • Fall risk should be tracked. Lean mass loss plus weight loss can transiently impair balance. Tai chi (Sherrington 2019 Cochrane high-certainty evidence for fall prevention) is a reasonable adjunct.
  • Slower rate of loss may be preferred. The 0.5-1.0% body weight per week target is appropriate; aggressive deficits that produce 1.5-2% per week in older adults disproportionately remove lean tissue.

Who else is at higher risk of muscle loss

Everyone losing weight loses some lean mass, but older adults are not the only group that loses proportionally more. If you fall into one of these groups, the protein-and-resistance-training plan is the priority, not an optional extra:

  • People with low protein intake. If appetite suppression has cut your protein well below the ~1.2 to 1.6 g/kg/day range, your body has little raw material to maintain muscle, and lean-mass loss accelerates.[11]
  • Sedentary people who do no resistance training. Without a strength stimulus, the body has less reason to hold onto muscle during a deficit, so the lean-mass share of weight lost runs higher.[12]
  • People losing weight very rapidly. Faster, larger deficits pull proportionally more from lean tissue, so very rapid responders should pay particular attention to protein and training.[10]
  • People who are already frail or have low muscle mass. Those with sarcopenic obesity or limited mobility have the least reserve and the most to lose functionally, which makes muscle preservation a central goal of their plan.[10]

A note on muscle-preserving drugs

Some research is exploring investigational drug combinations meant to preserve or build muscle during GLP-1 weight loss, for example pairing a GLP-1 with bimagrumab (an activin-receptor antibody) or other myostatin-pathway drugs under study. These are not FDA-approved for this purpose, their long-term safety and benefit are unproven, and they are not part of standard care. For now, the established way to protect muscle on Ozempic remains adequate protein plus resistance training. Treat anything beyond that as experimental and discuss it only with your prescriber.

How to measure: DXA vs BIA vs tape

The three practical body composition measurement options for Ozempic patients, in order of precision:

  • DXA (dual-energy X-ray absorptiometry): the gold standard. Directly measures fat mass, lean tissue, and bone mineral content with ~1-2% precision per scan. Available at most academic medical centers, some sports medicine clinics, and some commercial body-composition imaging providers (DexaFit, BodySpec). Cost is typically $50-$150 per scan. Recommended frequency: baseline plus every 6 months during active weight loss, then annually during maintenance. The radiation dose is very low (roughly the equivalent of a transatlantic flight per scan).
  • Bioelectrical impedance (BIA): home scales (Withings, RENPHO, InBody, Tanita) that send a low-amplitude electrical current through the body to estimate body composition. Precision is lower (~3-5%) and absolute values drift, but trend accuracy over weeks-to-months is reasonable when the measurement conditions are controlled (same time of day, same hydration state, empty bladder, no recent meal or exercise). For most patients tracking weekly trends, BIA is sufficient. Multi-frequency InBody scales at commercial gyms are more accurate than single-frequency consumer scales.
  • Tape measurements: the cheapest objective tracking method. Measure upper arm at the mid-belly of the biceps, thigh at the mid-belly of the quadriceps, calf at the maximum girth, waist at the navel, and hip at the maximum girth. Repeat monthly. Combined with monthly progress photos in consistent lighting, this is a low-cost adjunct to a DXA or BIA baseline.

Whichever method is used, the principle is consistency: pick one method, control the measurement conditions, and track the trend. The mistake is comparing a DXA value to a BIA value or switching between two different BIA scales mid-cycle and treating the absolute numbers as comparable. A program that bundles the device can make one consistent method easier to keep: HumeCare+ includes a Hume Pod body-composition tracker with its compounded semaglutide plan.

Bottom line

  • Muscle loss on Ozempic is real but PROPORTIONAL to the rate and total amount of weight lost — not a uniquely pharmacological effect. The Ozempic FDA label does not list muscle loss as a labeled adverse reaction.
  • The SURMOUNT-1 DXA substudy[1] (the highest- quality body composition data on a GLP-1 to date) showed roughly 75% of weight lost was fat mass and 25% was lean tissue, the same share as in the placebo arm. Direct semaglutide DXA data are more limited, and lean-mass shares across GLP-1 trials range from about 15% or less to 40-60% (Neeland 2024)[8].
  • Resistance training 2-3 days per week is the single highest- evidence protective intervention (Villareal 2017 NEJM[3]). Cardio alone is not protective.
  • Protein 1.2-1.6 g/kg body weight per day (Phillips 2016 [4], Pasiakos 2015[5], ISSN 2017 [6]).
  • Creatine 3-5 g/day (Kreider 2017 ISSN position stand [7]) is a reasonable adjunct that amplifies the resistance-training response, with no documented Ozempic interaction.
  • DXA scan at baseline and every 6 months is the gold standard for tracking. BIA scales are the next-best home option. Tape measurements plus progress photos are the cheapest objective adjunct.
  • Adults over 65 should treat DXA monitoring and structured resistance training as standard, not optional. The clinical stakes of lean mass loss are highest in this population.

Patients with cardiovascular disease, joint pathology, kidney disease, eating disorders, or other conditions limiting exertion or affecting protein metabolism should consult a clinician (and ideally a credentialed exercise physiologist or registered dietitian) before starting any new exercise or supplementation program. The SURMOUNT-1 DXA substudy[1] reports body composition data on tirzepatide; direct semaglutide DXA data is more limited, and the cross-trial inference to Ozempic-specific outcomes is reasonable but not the same as a head-to-head Ozempic body-composition trial.

Further reading

Our reviews

Providers that offer semaglutide

Telehealth providers we’ve reviewed. Each opens our full, independent review.

Also for this topic

For the muscle side: strength-training apps

Workout apps and coaching for the exercise side of your plan. Each opens our full, independent review.

We may earn a commission from featured partners. Learn more

See the full ranking →

Frequently Asked Questions

Ozempic produces lean tissue loss as part of weight loss, but the proportion (about 25% of total weight lost was lean mass in the SURMOUNT-1 DXA substudy on tirzepatide) was the same as in the placebo arm, not a unique drug effect. The Ozempic FDA label does NOT list muscle loss, sarcopenia, or myopathy as a labeled adverse reaction. Resistance training 2-3 days per week plus 1.2-1.6 g/kg of protein per day are the evidence-based protective interventions.
Direct semaglutide DXA data is more limited than tirzepatide data, but the best available estimate from the SURMOUNT-1 DXA substudy (Look 2025, PMID 39996356) is that about 25% of total weight lost was lean tissue at 72 weeks, a split that held across most subgroups. If the same split applied, a patient losing 15% of body weight on Ozempic (close to the STEP-1 mean) would lose roughly 3.75% of starting body weight as lean tissue and about 11% as fat mass — proportional to the rate and total amount of weight lost.
Three evidence-based levers, in order of effect size: (1) resistance training 2-3 days per week with compound lifts (squat, hinge, push, pull, carry), the only intervention with RCT-grade evidence for preserving lean mass in a caloric deficit; (2) protein 1.2-1.6 g/kg body weight per day; (3) creatine monohydrate 3-5 g/day as an adjunct that amplifies the resistance-training response. Cardio is helpful for cardiometabolic health but does not preserve muscle the way resistance training does.
DXA scan at baseline and every 6 months is the gold standard — it directly measures fat mass, lean tissue, and bone mineral content with ~1-2% precision. Bioelectrical impedance (BIA) scales (Withings, RENPHO, InBody) are the next-best home option, with ~3-5% precision and reasonable trend accuracy when conditions (hydration, time of day) are kept constant. Tape measurements at the upper arm, thigh, and waist are the cheapest objective marker and pair well with monthly photographs.
For most healthy adults under 65, the proportional lean tissue loss on Ozempic is not clinically dangerous — it tracks with what any rapid weight loss produces, and improved insulin sensitivity plus reduced visceral fat carries large net health benefit. The high-risk groups are adults over 65 (already at risk of sarcopenia), patients with low baseline lean mass, and patients with prior fragility fractures or osteoporosis. These groups should consider DXA monitoring, structured resistance training, and protein supplementation as standard rather than optional.
Some — but the regain pattern after stopping a GLP-1 favors fat over lean tissue in most reported observational data. The STEP-4 trial showed substantial weight regain after semaglutide discontinuation, and body composition data suggests the regained weight is disproportionately fat mass. This is why active resistance training during AND after a GLP-1 cycle is the most important intervention: it tilts the body composition trajectory toward preserved or rebuilt lean tissue regardless of whether the drug is continued.
Yes — building muscle while in a caloric deficit is harder than building at maintenance or in a surplus, but it is achievable, particularly for people new to resistance training or returning after a long break, where the anabolic stimulus of training is strong enough to overcome the deficit headwind. The key combination is resistance training 2 - 3 times per week with compound movements (squat, hinge, push, pull, carry) and protein at 1.2 - 1.6 g per kilogram of body weight per day. For experienced lifters, net muscle gain during an aggressive caloric deficit is less likely, but maintaining or modestly increasing lean mass is a realistic goal. The Villareal 2017 NEJM trial in older adults showed that resistance training during caloric restriction can produce both fat loss and preserved or improved physical function, which is the closest available analog for this question. The practical framing on Ozempic is that resistance training is a required component of the treatment protocol, not an optional add-on, and some muscle growth alongside fat loss is possible for many people who start training seriously.
Yes — lean mass lost during Ozempic therapy can be rebuilt, because skeletal muscle is dynamic tissue that responds to resistance training stimulus at any age. The most important window is during treatment: active resistance training and adequate protein intake during the GLP-1 cycle minimize how much muscle is lost and can produce modest lean mass gains at the same time fat is being shed. After stopping Ozempic, the picture is more nuanced — STEP-4 data shows weight regain after discontinuation, and body composition data suggests regained weight skews toward fat rather than lean tissue when training and protein habits are not in place. With deliberate resistance training and sustained protein intake after stopping, lean mass can rebuild progressively over months. Without that effort, returning weight tends to add more fat than muscle. The upshot is that muscle loss from Ozempic is not permanent, but reversing it requires the same active levers — resistance training and protein — whether the drug is continued or stopped.
Some investigational drug combinations are being studied to preserve or build muscle during GLP-1 weight loss, for instance pairing a GLP-1 with bimagrumab or other myostatin-pathway drugs. These are experimental, not FDA-approved for this purpose, and their long-term safety and benefit are unproven, so they are not part of standard care. For now, the established way to protect muscle on Ozempic is adequate protein plus resistance training, not an additional medication. If you are interested in emerging options, discuss them only with your prescriber.

References

  1. 1.Look M, Dunn JP, Kushner RF, Cao D, Karjanlahti L, Suttak M, Wang H, Sapin H, Mather KJ, Stefanski A. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes Obes Metab. 2025. PMID: 39996356.
  2. 2.Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF; STEP 1 Study Group. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021. PMID: 33567185.
  3. 3.Villareal DT, Aguirre L, Gurney AB, Waters DL, Sinacore DR, Colombo E, Armamento-Villareal R, Qualls C. Aerobic or Resistance Exercise, or Both, in Dieting Obese Older Adults. N Engl J Med. 2017. PMID: 28514618.
  4. 4.Phillips SM, Chevalier S, Leidy HJ. Protein "requirements" beyond the RDA: implications for optimizing health. Appl Physiol Nutr Metab. 2016. PMID: 26960445.
  5. 5.Pasiakos SM, Cao JJ, Margolis LM, Sauter ER, Whigham LD, McClung JP, Rood JC, Carbone JW, Combs GF Jr, Young AJ. Optimized dietary strategies to protect skeletal muscle mass during periods of unavoidable energy deficit. FASEB J. 2015. PMID: 25550460.
  6. 6.Jäger R, Kerksick CM, Campbell BI, Cribb PJ, Wells SD, Skwiat TM, Purpura M, Ziegenfuss TN, Ferrando AA, Arent SM, Smith-Ryan AE, Stout JR, Arciero PJ, Ormsbee MJ, Taylor LW, Wilborn CD, Kalman DS, Kreider RB, Willoughby DS, Hoffman JR, Krzykowski JL, Antonio J. International Society of Sports Nutrition Position Stand: protein and exercise. J Int Soc Sports Nutr. 2017. PMID: 28642676.
  7. 7.Kreider RB, Kalman DS, Antonio J, Ziegenfuss TN, Wildman R, Collins R, Candow DG, Kleiner SM, Almada AL, Lopez HL. International Society of Sports Nutrition position stand: safety and efficacy of creatine supplementation in exercise, sport, and medicine. J Int Soc Sports Nutr. 2017. PMID: 28615996.
  8. 8.Neeland IJ, Linge J, Birkenfeld AL. Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies. Diabetes Obes Metab. 2024. PMID: 38937282.
  9. 9.Cava E, Yeat NC, Mittendorfer B. Preserving Healthy Muscle during Weight Loss. Adv Nutr. 2017. PMID: 28507015.
  10. 10.Mechanick JI, Butsch WS, Christensen SM, et al. Strategies for minimizing muscle loss during use of incretin-mimetic drugs for treatment of obesity. Obes Rev. 2025. PMID: 39295512.
  11. 11.Longland TM, Oikawa SY, Mitchell CJ, et al. Higher compared with lower dietary protein during an energy deficit combined with intense exercise promotes greater lean mass gain and fat mass loss: a randomized trial. Am J Clin Nutr. 2016. PMID: 26817506.
  12. 12.Pasiakos SM, Cao JJ, Margolis LM, et al. Effects of high-protein diets on fat-free mass and muscle protein synthesis following weight loss: a randomized controlled trial. FASEB J. 2013. PMID: 23739654.
  13. 13.Bauer J, Biolo G, Cederholm T, et al. Evidence-based recommendations for optimal dietary protein intake in older people: a position paper from the PROT-AGE Study Group. J Am Med Dir Assoc. 2013. PMID: 23867520.

Tirzepatide (Mounjaro, Zepbound) Muscle Loss: SURMOUNT-1 DXA Lean-Mass Evidence

Muscle loss on tirzepatide is real but proportional to weight lost, not unique to the drug. SURMOUNT-1 DXA (Look 2025): ~75% fat / ~25% lean — same split as placebo. Zepbound and Mounjaro FDA labels do NOT list muscle loss as an adverse reaction.

14 min read

Can You Lose Weight on Semaglutide Without Exercise? Honest Evidence Review

Yes. STEP-1 reached -14.9% body weight at 68 weeks with diet counseling only — supervised exercise was not the intervention. The catch: without resistance training, roughly 25-40% of the weight you lose comes from lean tissue, not fat.

11 min read

Does Creatine Help With Weight Loss? Honest Evidence Review

Creatine does not cause fat loss. It raises scale weight 1–2 kg via intracellular water in weeks 1–4, then, with resistance training, adds lean mass (about 1.4 kg in older-adult trials). A performance supplement, not a weight-loss drug.

9 min read

Does Pilates Cause Weight Loss? Honest Evidence Review

Pilates does not produce clinically meaningful weight loss directly. Modest calorie burn and improvements in core strength + flexibility. Best paired with caloric deficit + resistance training.

17 min read

Wegovy vs Ozempic: Same Molecule, Different FDA Approvals — Evidence Review

Wegovy and Ozempic are the same semaglutide molecule at different maximum doses (7.2 mg vs 2.0 mg weekly) with different FDA indications. STEP-1 showed -14.9% body weight on Wegovy 2.4 mg; SUSTAIN-6 and SELECT carry the CV evidence base. Decision walkthrough.

15 min read

Ozempic Long-Term Side Effects: Chronic-Exposure Evidence Review

What do we actually know about taking Ozempic for 3, 5, 7+ years? SELECT (median 3.3 yr), SUSTAIN-6 (median 2.1 yr), LEADER liraglutide analog (3.8 yr), FAERS post-marketing data, NAION signal (Hathaway 2024), gallbladder, pancreatitis, kidney, thyroid, mood, pregnancy.

16 min read

Where to get semaglutide (Ozempic / Wegovy) safely: vetted online providers

Vetted telehealth providers that prescribe online. We compare pricing, form, and states served.

No insurance needed · vetted by our editors

WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. How we make money

8.3

Collective

The lowest flat medication price if you can absorb an annual membership fee

Read full review →

From $59/mo (+ required membership)

Get started →
8.3

CoreAge Rx

Lowest-price compounded semaglutide and tirzepatide with one flat price at every dose

Read full review →

From $79/mo (“starting at” price)

Get started →
7.8

Embody

Low flat-rate compounded GLP-1 pricing at every dose

Read full review →

From $79/mo (sale price)

Get started →